This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-10. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
=== Structural Variants === The most widely used sortase in biological and medical applications is the SrtA enzyme found in staphylococcus aureus bacteria, which recognizes an LPXTG binding motif. Different sortase enzymes found in staphylococcus and other bacteria have other recognition sequences. SrtB for example recognizes a NPQTN binding sequence. These other sortase variants have different properties including different binding motifs and reaction efficiencies. To use the sortase enzyme in broader applications new variations of the enzyme have been developed to exhibit desired properties. SrtA variants that exhibit similar kinetics and catalytic efficiency to the wild type have been engineered using directed evolution. This process induces mutations in the natural enzyme and selects for mutations that result in the desired properties. SrtA variants have been developed with different binding motifs (LPXSG and LAXTG). Another sortase variant, eSrtA, was specifically developed to have improved kinetics, while still other variants were developed to operate in the absence of calcium.
Again there are a few anomalies along the way: for example, as single atoms neither actinium nor thorium actually fills the 5f subshell, and lawrencium does not fill the 6d shell, but all these subshells can still become filled in chemical environments. For a very long time, the seventh row was incomplete as most of its elements do not occur in nature. The missing elements beyond uranium started to be synthesized in the laboratory in 1940, when neptunium was made. (However, the first element to be discovered by synthesis rather than in nature was technetium in 1937.) The row was completed with the synthesis of tennessine in 2009 (the last element oganesson had already been made in 2002), and the last elements in this seventh row were given names in 2016.
Mental health encompasses emotional, psychological, and social well-being, influencing cognition, perception, and behavior. Mental health plays a crucial role in an individual's daily life when managing stress, engaging with others, and contributing to life overall. According to the World Health Organization (WHO), it is a "state of well-being in which the individual realizes their abilities, can cope with the normal stresses of life, can work productively and fruitfully, and can contribute to their community". It likewise determines how an individual handles stress, interpersonal relationships, and decision-making. Mental health includes subjective well-being, perceived self-efficacy, autonomy, competence, intergenerational dependence, and self-actualization of one's intellectual and emotional potential, among others. From the perspectives of positive psychology or holism, mental health is thus not merely the absence of mental illness. Rather, it is a broader state of well-being that includes an individual's ability to enjoy life and to create a balance between life activities and efforts to achieve psychological resilience. Cultural differences, personal philosophy, subjective assessments, and competing professional theories all affect how one defines "mental health".
=== International coordination === International Day Against Drug Abuse and Illicit Trafficking Interpol United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances
Sources: en.wikipedia.org
== History == NBOMe-LAD was first described in the literature by 2022. It was described in a patent by Andrew Kruegel and Gilgamesh Pharmaceuticals. Various other NBOMe-type analogues of LSD and related compounds were also described.
No nihonium atoms were observed after chemical separation, implying an unexpectedly large retention of nihonium atoms on PTFE surfaces. This experimental result for the interaction limit of nihonium atoms with a PTFE surface (−ΔHPTFEads(Nh) > 45 kJ/mol) disagrees significantly with previous theory, which expected a lower value of 14.00 kJ/mol. This suggests that the nihonium species involved in the previous experiment was likely not elemental nihonium but rather nihonium hydroxide, and that high-temperature techniques such as vacuum chromatography would be necessary to further probe the behaviour of elemental nihonium. Bromine saturated with boron tribromide has been suggested as a carrier gas for experiments on nihonium chemistry; this oxidises nihonium's lighter congener thallium to thallium(III), providing an avenue to investigate the oxidation states of nihonium, similar to earlier experiments done on the bromides of group 5 elements, including the superheavy dubnium. A 2024 experiment at the GSI, producing 284Nh via the 243Am+48Ca reaction as daughter of 288Mc, studied the adsorption of nihonium and moscovium on SiO2 and gold surfaces. The adsorption enthalpy of nihonium on SiO2 was determined experimentally as −ΔHSiO2ads(Nh) = 58+8−3 kJ/mol (68% confidence interval). Nihonium was determined to be less reactive with the SiO2 surface than its lighter congener thallium, but more reactive than its closed-shell neighbours copernicium and flerovium. This arises because of the relativistic stabilisation of the 7p1/2 shell.
In 2017, Forever 21 produced a clothing line in partnership with Taco Bell, featuring branded T-shirts and sweatshirts, as well as bodysuits made to look like Border Sauce packets. In November 2019, Taco Bell announced Taco Bell's Taco Shop, an online store with Taco Bell branded merchandise including hoodies and tees, holiday ornaments, inflatable sauce packets, and wedding-related items.
UVA radiation plays a role in the induction of melanoma and UVB radiation is the primary cause of squamous cell carcinomas. It is suggested that the antimutagenic properties of Colostrinin are achieved via multiple mechanisms - by decreasing intracellular levels of ROS and so preventing DNA damage and by increasing the efficiency of natural DNA repair mechanisms.
Everyone agrees on the nature and diagnosis of severe GH deficiency, but what are the edges and variations? How should marked constitutional delay be distinguished from partial GH deficiency? To what extent is "normal shortness" a matter of short children naturally making less growth hormone? Can a child make GH in response to a stimulation test but fail to make enough in "daily life" to grow normally? If a stimulation test is used to define deficiency, what GH cutoff should be used to define normal? It was the ethical questions that were new. Whole meetings were devoted to these questions; pediatric endocrinology had become a specialty with its own bioethics issues. Despite the price, the 1990s became an era of experimentation to see what else growth hormone could help. The medical literature of the decade contains hundreds of reports of small trials of GH use in nearly every type of growth failure and shortness imaginable. In most cases, the growth responses were modest. For conditions with a large enough potential market, more rigorous trials were sponsored by pharmaceutical companies that were making growth hormone to achieve approval to market for those specific indications. Turner syndrome and chronic kidney failure were the first of these "nonGH-deficient causes of shortness" to receive FDA approval for GH treatment, and Prader–Willi syndrome and intrauterine growth retardation followed. Similar expansion of use occurred in Europe. One obvious potential market was adult GH deficiency.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.